CA
AGIO icon

Calton & Associates’s Agios Pharmaceuticals AGIO Stock Holding History

Calton & Associates’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-300
Closed -$23K – 367
2017
Q4 		$23K Buy
+300
New +$18.9K 0.01% 861

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Calton & Associates's AGIO Position: Q1 2018 in Review

Calton & Associates sold out of Agios Pharmaceuticals (AGIO) in Q1 2018, closing a stake of 300 shares — an estimated $23K sold.

Calton & Associates first reported a position in AGIO in Q4 2017 and held it in 1 quarter. The position peaked at $23K in Q4 2017. 198 funds tracked by Wall St. Rank hold AGIO as of Q1 2018.

  • Calton & Associates reported no remaining Agios Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 300 Agios Pharmaceuticals shares in Q1 2018, an estimated $23K.
  • Calton & Associates first reported a position in Agios Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's Agios Pharmaceuticals position peaked at $23K in Q4 2017.
  • 198 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.